📰 What This Document Is 📰

This document is a Form 6-K, which is a report filed by a foreign private issuer (GSK plc) with the U.S. Securities and Exchange Commission. Think of it as an international progress report that lets U.S. investors know about important operational updates happening outside the United States. This specific report, issued on April 20, 2026, focuses on a major regulatory milestone: the approval of one of GSK's key cancer drugs, Blenrep, in the Chinese market.

👉 The main headline is that GSK's drug, Blenrep, has received approval from China's National Medical Products Administration (NMPA) for a challenging form of cancer, positioning the company for significant growth in a huge international market.

🔬 What Blenrep Does and Why It Matters 🧬

In simple terms, GSK manufactures highly advanced pharmaceuticals, and Blenrep (belantamab mafodotin) is a sophisticated medication designed to target a specific protein called BCMA. This drug falls into a class of drugs called Antibody-Drug Conjugates (ADCs), which are complex chemical tools that act like guided missiles. They carry a potent chemical payload directly to cancer cells that display the target protein, maximizing effectiveness while minimizing damage to healthy tissue.

👉 Multiple myeloma is the third most common blood cancer worldwide, and since it often becomes resistant to multiple treatments, there is an urgent need for novel, effective therapies like Blenrep.

🇨🇳 New China Approval for Blenrep 🇨🇳

GSK announced that the National Medical Products Administration (NMPA) of China has approved Blenrep in combination with bortezomib and dexamethasone (BVd) for treating adults with relapsed or refractory multiple myeloma. This approval is especially impactful because Blenrep is the only anti-BCMA ADC approved in this setting within China, giving patients a unique treatment option.

• Approval Details: The approval covers the combination of Blenrep with bortezomib and dexamethasone (BVd).
• Clinical Basis: This breakthrough approval was supported by data from the pivotal DREAMM-7 phase III clinical trial.
• Convenience: Crucially, Blenrep is touted as the only fully outpatient anti-BCMA therapy, meaning patients can receive treatment at any site of care without complex pre-administration regimens or needing to be hospitalized.

👉 Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, highlighted the combination's impact, stating: "Today's approval of Blenrep brings anti-BCMA therapy to patients in China... introducing a differentiated mechanism of action with the potential to help slow disease progression and extend survival."

📈 Pivotal Trial Results (DREAMM-7) 💡

The drug’s efficacy and safety were rigorously tested in the DREAMM-7 phase III trial. This multi-center, randomized trial compared the Blenrep combination (BVd) against a daratumumab-based triplet combination (DVd) in patients with relapsed or refractory multiple myeloma. These results provide the quantitative evidence for the NMPA approval.

• Progress-Free Survival (PFS): The combination with Blenrep (BVd) showed a significantly superior result, nearly tripling the median PFS at 36.6 months compared to 13.4 months for the comparator group (a difference of 23.2 months). PFS measures how long the cancer remains under control.
• Overall Survival (OS): The trial met its key secondary endpoint for Overall Survival, demonstrating a statistically significant 42% reduction in the risk of death at a median follow-up of 39.4 months (BVd vs. DVd).
• Long-Term Rates: The three-year OS rate was 74% in the Blenrep combination arm (BVd) versus 60% in the comparator arm (DVd).
• Patient Profile: The combination benefited a broad range of patients, including those who were considered poor prognostic risks (e.g., those with high-risk cytogenetics).

👉 While the drug has clinical benefits, the trial also noted that eye-related side effects associated with Blenrep can be managed and reversed with appropriate dose modifications, keeping the discontinuation rate low (≤9%).

🔬 The Science of Blenrep and Multiple Myeloma 🧬

To understand the drug's impact, it helps to know the science behind it. Multiple myeloma is generally considered treatable but not curable, requiring constant research into new treatments. Blenrep itself is described as a monoclonal ADC, meaning it consists of a humanized BCMA antibody linked to a potent chemical agent (monomethyl auristatin F).

• Mechanism: Blenrep specifically targets B-cell maturation antigen (BCMA), which is found on the surface of certain cancer cells. By concentrating the cytotoxic agent at the cancer site, it offers a differentiated mechanism of action that bypasses potential resistance pathways.
• Global Status: Blenrep is already approved in the US, requiring at least two prior lines of therapy. Furthermore, it has achieved numerous regulatory approvals in other major markets, including the European Union, UK, Japan, Canada, Switzerland, Brazil, and Australia.

👉 The global scope of regulatory approvals confirms Blenrep's established role as a standard-of-care treatment option for the disease.

🚀 Oncology Pipeline & Future Growth 🚀

While the focus of this filing is the China approval, GSK continues to expand its oncology portfolio. The company's overall ambition is to increase quality of life and change the course of disease by expanding beyond its current focus on blood and women's cancers.

• Solid Tumor Focus: GSK is actively expanding into lung and gastrointestinal cancers, as well as other solid tumors.
• Priority Programs: The company is accelerating priority programs, including Antibody-Drug Conjugates (ADCs) that target B7-H3 and B7-H4.
• Key Drug Candidate: They are also focusing on IDRX-42, which is described as a highly selective KIT tyrosine kinase inhibitor.

👉 This strategic pipeline depth signals GSK's intent to maintain leadership and drive growth by diversifying its treatment options across various cancer types.

🌍 Market Context and Operational Scale 🌐

The need for treatments like Blenrep is underscored by the sheer size of the cancer burden. In China alone, the incidence of multiple myeloma has doubled, resulting in approximately 30,000 new cases annually, and mortality rates have risen by 50% over the past three decades.

• Global Scale: Globally, there are approximately 180,000 new cases of multiple myeloma diagnosed every year, creating a massive and persistent market demand for effective, manageable therapies.
• Treating Needs: Because many patients are treated in community cancer settings (outside of major academic centers), the need for effective drugs with manageable side effects that can be administered outside of a hospital is extremely high.

👉 The growth of multiple myeloma cases in China, combined with the convenience of outpatient administration, represents a substantial and favorable market opportunity for GSK.

📞 Corporate Contacts & Information ✉️

For readers needing more information about GSK, investors, or media, the following contact details and resources were provided in the filing.

• Website: Find out more at www.gsk.com.
• Media Contacts (London): Tim Foley at +44 (0) 20 8047 5502; Madison Goring at +44 (0) 20 8047 5502.
• Washington DC Contacts: Kathleen Quinn at +1 202 603 5003; Alison Hunt at +1 540 742 3391.
• Investor Relations (Philadelphia): Multiple contacts listed, including James Dodwell at +44 (0) 20 8047 2406, and Jeff McLaughlin at +1 215 751 7002.

🧠 The Analogy 🧭

Imagine a massive, complex ocean where multiple types of boats (cancer) are struggling to survive. Blenrep is not just a single life raft; it's a highly specialized, guided rescue vessel (the ADC). This vessel has a unique chemical payload that can navigate specifically to the most resistant boats (the cancer cells), drop off the cure, and avoid sinking the healthy boats (the patient's body). Because the process can be done at any port (outpatient infusion), it makes treatment accessible to even the smallest local harbors (community cancer settings).

🧩 Final Takeaway 🥇

GSK's successful NMPA approval of Blenrep in China is a major international milestone, validating the drug's effectiveness with groundbreaking data from the DREAMM-7 trial. This expansion solidifies GSK's market position, capitalizing on the growing incidence of multiple myeloma in China while fueling investment into next-generation cancer treatments worldwide.